Harvey Capital Management Inc. Acquires 249,790 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Harvey Capital Management Inc. increased its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 1,419.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 267,390 shares of the company’s stock after buying an additional 249,790 shares during the quarter. Harvey Capital Management Inc.’s holdings in Aquestive Therapeutics were worth $952,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Financial Advocates Investment Management increased its position in shares of Aquestive Therapeutics by 28.2% during the 4th quarter. Financial Advocates Investment Management now owns 50,000 shares of the company’s stock valued at $178,000 after purchasing an additional 11,000 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Aquestive Therapeutics during the fourth quarter valued at about $69,000. Janney Montgomery Scott LLC increased its holdings in Aquestive Therapeutics by 6.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock worth $3,505,000 after buying an additional 61,200 shares during the last quarter. SG Americas Securities LLC raised its position in Aquestive Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock worth $117,000 after acquiring an additional 7,347 shares during the period. Finally, Barclays PLC boosted its stake in Aquestive Therapeutics by 285.4% in the third quarter. Barclays PLC now owns 99,312 shares of the company’s stock valued at $495,000 after acquiring an additional 73,542 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Stock Down 0.7 %

AQST stock opened at $2.97 on Wednesday. Aquestive Therapeutics, Inc. has a twelve month low of $2.24 and a twelve month high of $6.23. The firm has a market capitalization of $270.80 million, a PE ratio of -6.60 and a beta of 2.67. The stock has a 50-day simple moving average of $3.41 and a two-hundred day simple moving average of $4.21.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on AQST shares. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Finally, Leerink Partners upped their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Aquestive Therapeutics has an average rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.